Back to Search
Start Over
Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2019 Nov 15; Vol. 58 (22), pp. 3313-3318. Date of Electronic Publication: 2019 Jul 10. - Publication Year :
- 2019
-
Abstract
- Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder, and only a few cases have been reported to be complicated with autoimmune hemolytic anemia (AIHA). A 43-year-old man who presented with multiple swollen lymph nodes was diagnosed with iMCD. He was also diagnosed with AIHA based on laboratory findings, including the results of a bone marrow aspiration study. The patient was treated with tocilizumab; however, the effect was limited, probably due to anti-drug antibodies. Tocilizumab was therefore switched to rituximab, and his anemia was improved. Complication with AIHA should be carefully considered when iMCD patients present with severe anemia.
- Subjects :
- Adult
Anemia, Hemolytic, Autoimmune diagnosis
Anemia, Hemolytic, Autoimmune drug therapy
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Humans
Male
Rituximab therapeutic use
Anemia, Hemolytic, Autoimmune complications
Castleman Disease complications
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 58
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 31292389
- Full Text :
- https://doi.org/10.2169/internalmedicine.2989-19